Clinical Features Predictive of Survival in Patients With Vitreoretinal Lymphoma: Analysis of 70 Patients at a Single Ocular Oncology Center

被引:17
作者
Dalvin, Lauren A. [1 ,2 ]
Lim, Li-Anne S. [1 ]
Ancona-Lezama, David [1 ]
Mazloumi, Mehdi [1 ]
Chang, Michael [1 ]
Porcu, Pierluigi [3 ,4 ]
Martinez, Nina L. [3 ,4 ,5 ]
Glass, Jon [3 ,4 ,5 ]
Mashayekhi, Arman [1 ]
Shields, Carol L. [1 ]
机构
[1] Thomas Jefferson Univ, Wills Eye Hosp, Ocular Oncol Serv, Philadelphia, PA 19107 USA
[2] Mayo Clin, Dept Ophthalmol, Rochester, MN USA
[3] Thomas Jefferson Univ, Div Hematol Malignancies & Hematopoiet Stem Cell, Dept Med Oncol, Philadelphia, PA 19107 USA
[4] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA
[5] Thomas Jefferson Univ, Dept Neurol, Philadelphia, PA 19107 USA
来源
ASIA-PACIFIC JOURNAL OF OPHTHALMOLOGY | 2020年 / 9卷 / 02期
关键词
central nervous system; eye; lymphoma; survival; vitreoretinal; NERVOUS-SYSTEM LYMPHOMA; B-CELL LYMPHOMA; INTRAOCULAR LYMPHOMA; ASSOCIATION; MULTICENTER; SARCOMA;
D O I
10.1097/APO.0000000000000274
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: The aim of this study was to identify clinical factors predictive of time to central nervous system (CNS) lymphoma or death in patients with vitreoretinal lymphoma (VRL). Design: Retrospective cohort study. Methods: Patients with VRL (n = 95 patients) from Januray 1, 1984 to July 30, 2018 were identified at a single ocular oncology center and records were retrospectively reviewed. Outcomes included Kaplan-Meier estimated time to CNS lymphoma and death. Results: There were 95 patients with VRL diagnosed at mean age 67 years, of which 70 patients had follow-up with the ocular oncology service. Mean time to CNS lymphoma in patients with isolated VRL was 56 months and did not differ by age, sex, bilateral ocular involvement, retinal infiltration, subretinal pigment epithelial (sub-RPE) infiltration, or treatment with prophylactic systemic chemotherapy (P > 0.05). Mean time to death was 66 months and did not differ when comparing those with CNS lymphoma diagnosed before VRL versus after VRL versus no CNS lymphoma at any time (67 vs 60 vs 64 months, P > 0.05). Presence of sub-RPE infiltration was associated with shorter mean time to death (46 vs 76 months, P = 0.04, odds ratio 1.9). Older patient age was associated with increased risk of death (odds ratio 1.0, P = 0.02). The mean time to death did not differ by sex, bilateral ocular involvement, retinal infiltration, timing of CNS or systemic lymphoma, or treatment with prophylactic systemic chemotherapy (P > 0.05). Conclusions: Patients with VRL presenting with sub-RPE infiltration could have shorter mean survival time. Further studies are required to confirm these findings and determine whether sub-RPE infiltration is associated with more aggressive CNS lymphoma.
引用
收藏
页码:110 / 116
页数:7
相关论文
共 25 条
[1]   Association of Disease Location and Treatment With Survival in Diffuse Large B-Cell Lymphoma of the Eye and Ocular Adnexal Region [J].
Ahmed, Aseef H. ;
Foster, Stephen ;
Shields, Carol L. .
JAMA OPHTHALMOLOGY, 2017, 135 (10) :1062-1068
[2]  
Barr C C, 1975, Surv Ophthalmol, V19, P224
[3]   Ocular and central nervous system lymphoma:: clinical features and diagnosis [J].
Cassoux, N ;
Merle-Beral, H ;
Leblond, V ;
Bodaghi, B ;
Miléa, D ;
Gerber, S ;
Fardeau, C ;
Reux, I ;
Xuan, KH ;
Chan, CC ;
LeHoang, P .
OCULAR IMMUNOLOGY AND INFLAMMATION, 2000, 8 (04) :243-250
[4]   Role of systemic high-dose methotrexate and combined approaches in the management of vitreoretinal lymphoma: A single center experience 1990-2018 [J].
Castellino, Alessia ;
Pulido, Jose S. ;
Johnston, Patrick B. ;
Ristow, Kay M. ;
Bennani, N. Nora ;
Inwards, David J. ;
Macon, William R. ;
Micallef, Ivana N. M. ;
King, Rebecca L. ;
Salomao, Diva R. ;
Witzig, Thomas E. ;
Habermann, Thomas M. ;
Nowakowski, Grzegorz S. .
AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (03) :291-298
[5]  
Chan CC, 2013, DISCOV MED, V15, P93
[6]   Primary Vitreoretinal Lymphoma: A Report from an International Primary Central Nervous System Lymphoma Collaborative Group Symposium [J].
Chan, Chi-Chao ;
Rubenstein, James L. ;
Coupland, Sarah E. ;
Davis, Janet L. ;
Harbour, J. William ;
Johnston, Patrick B. ;
Cassoux, Nathalie ;
Touitou, Valerie ;
Smith, Justine R. ;
Batchelor, Tracy T. ;
Pulido, Jose S. .
ONCOLOGIST, 2011, 16 (11) :1589-1599
[7]   Targetable genetic features of primary testicular and primary central nervous system lymphomas [J].
Chapuy, Bjoern ;
Roemer, Margaretha G. M. ;
Stewart, Chip ;
Tan, Yuxiang ;
Abo, Ryan P. ;
Zhang, Liye ;
Dunford, Andrew J. ;
Meredith, David M. ;
Thorner, Aaron R. ;
Jordanova, Ekaterina S. ;
Liu, Gang ;
Feuerhake, Friedrich ;
Ducar, Matthew D. ;
Illerhaus, Gerald ;
Gusenleitner, Daniel ;
Linden, Erica A. ;
Sun, Heather H. ;
Homer, Heather ;
Aono, Miyuki ;
Pinkus, Geraldine S. ;
Ligon, Azra H. ;
Ligon, Keith L. ;
Ferry, Judith A. ;
Freeman, Gordon J. ;
van Hummelen, Paul ;
Golub, Todd R. ;
Getz, Gad ;
Rodig, Scott J. ;
de Jong, Daphne ;
Monti, Stefano ;
Shipp, Margaret A. .
BLOOD, 2016, 127 (07) :869-881
[8]   OCULAR RETICULUM-CELL SARCOMA [J].
CHAR, DH ;
MARGOLIS, L ;
NEWMAN, AB .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1981, 91 (04) :480-483
[9]   Clinical Features and Treatment Outcomes of Vitreoretinal Lymphoma according to Its Association with CNS Lymphoma [J].
Cho, Bum-Joo ;
Kim, Dong Yoon ;
Park, Un Chul ;
Lee, Joo Yong ;
Yoon, Young Hee ;
Yu, Hyeong Gon .
OCULAR IMMUNOLOGY AND INFLAMMATION, 2018, 26 (03) :365-371
[10]   CHECKPOINT INHIBITOR IMMUNE THERAPY Systemic Indications and Ophthalmic Side Effects [J].
Dalvin, Lauren A. ;
Shields, Carol L. ;
Orloff, Marlana ;
Sato, Takami ;
Shields, Jerry A. .
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2018, 38 (06) :1063-1078